SK Biopharmaceuticals will pay Insilico Medicine more than $2.5 billion for AI-driven neuroimmune drug discovery. That’s the headline; the upfront and near-term milestone payment is $18 million.
Under the Insilico-SK Biopharm collaboration, Insilico’s Pharma.AI engine designs and optimizes candidates for neuroinflammatory, neurodegenerative, and rare neurological diseases. SK takes over at late-stage development and commercialization, drawing on the infrastructure it built with Xcopri (cenobamate), its FDA-approved anti-seizure medicine. The remainder sits behind development, regulatory, and commercial milestones, plus single-digit royalties.
Compare the structure to Insilico’s March deal with Eli Lilly, worth up to $2.75 billion. Lilly paid $115 million upfront — about 4.2% of the headline. SK’s paying 0.7%. Both deals read as AI platform bets, but the upfront split tells you who blinked: Lilly bought at a platform valuation; SK bought options on future candidates. Insilico carries the discovery risk either way.
Specific disease targets weren’t disclosed. SK gets the commercialization rights to whatever Insilico produces, fitting the Korean company’s stated goal of expanding beyond epilepsy into CNS broadly. No lead asset, no stage, no peak-sales figure has been named.
This is the largest deal Insilico has struck with an Asia-Pacific partner to date. Its deal log now includes Servier ($888 million, cancer), Qilu Pharmaceutical ($120 million, cardiometabolic), and a pair of CNS pacts with Hygtia Therapeutics and Tenacia Biotechnology. No close date was announced.
Diana Kowalski